Phase Ii Study of Weekly Irinotecan Plus Cisplatin in Patients with Previously Untreated Extensive-Stage Extrapulmonary Small Cell Carcinoma

Shidai Jin,Tongshan Wang,Xiaofeng Chen,Bei Xu,Jing Sun,Renhua Guo,Yongqian Shu
DOI: https://doi.org/10.1159/000329609
2011-01-01
Onkologie
Abstract:Background: The regimen of weekly irinotecan plus cisplatin (IP) is used for treatment of small cell lung cancer (SCLC). We conducted a phase II trial to evaluate the efficacy and toxicity of weekly IP in patients with previously untreated extensive-stage extrapulmonary small cell carcinoma (EPSCC). Patients and Methods: 15 patients with previously untreated extensive-stage EPSCC were enrolled. They received 60 mg/m(2) of irinotecan on days 1, 8 and 15, and 25 mg/m(2) of cisplatin days 1-3. This regimen was given every 28 days, and efficacy was evaluated after 2 cycles. Results: Objective responses were observed in 10 patients (66.7%), including 3 complete responses (20%) and 7 partial responses (46.7%). The median time to tumor progression was 4.5 months, the median survival time was 11.4 months, and the 1-year survival rate was 46.7%. Toxicities were relatively mild, and there were no treatment-related deaths. Conclusions: Weekly IP has significant activity in extensive-stage EPSCC. The regimen was well tolerated, with acceptable myelosuppression and treatment-related diarrhea.
What problem does this paper attempt to address?